Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Veracyte (NASDAQ:VCYT) released its quarterly earnings results on Thursday. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13, FiscalAI reports. The business had revenue of $150.32 million during the quarter, compared to the consensus estimate of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.41%. The business’s quarterly revenue was up 15.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.44 earnings per share.

Here are the key takeaways from Veracyte’s conference call:

• Strong Q2 results: Revenue rose 15% year over year to $150.3 million, testing volume increased 13% to approximately 51,000 tests, and adjusted EBITDA grew 23% to $44 million, or 29.2% of revenue. The company generated $45.8 million in operating cash flow and ended the quarter with $485.2 million in cash and short-term investments.
• Veracyte raised its 2026 revenue outlook to $590 million-$596 million, reflecting 14%-15% growth, while maintaining adjusted EBITDA guidance above 26%. The outlook assumes approximately 20% Decipher revenue growth and excludes contributions from the recently launched Prosigna LDT and TrueMRD products.
• The company launched Prosigna LDT for ER-positive, HER2-negative breast cancer and TrueMRD for recurrence monitoring in muscle-invasive bladder cancer. Early physician and patient response has been encouraging, more than 100 institutions are engaged on Prosigna, and Veracyte is expanding its sales force and investing in electronic health-record integration.
• Decipher Prostate volume expectations were reduced by approximately 1,000 tests for 2026, primarily because low-risk testing is growing only at a single-digit rate after an NCCN guideline change removed genomic testing from active-surveillance recommendations. Management expects additional clinical studies, with initial readouts beginning as early as 2027, to support potential future adoption.
• Afirma continued to gain traction, with volume up 10% and revenue up 18% year over year to approximately 18,600 tests. Higher reimbursement, pricing improvements, market-share gains, and the V2 transcriptome workflow’s lower no-result rate supported growth and improved testing gross margins.

Veracyte Stock Down 22.5%

VCYT stock traded down $13.46 during trading on Friday, hitting $46.32. 5,993,941 shares of the company’s stock traded hands, compared to its average volume of 948,309. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of 32.85 and a beta of 1.93. Veracyte has a 52 week low of $22.92 and a 52 week high of $60.91. The stock has a fifty day moving average price of $53.72 and a two-hundred day moving average price of $42.32.

Insiders Place Their Bets

In other news, CEO Marc Stapley sold 138,051 shares of Veracyte stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the completion of the transaction, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at approximately $22,077,559.28. The trade was a 23.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Leite sold 13,975 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.07, for a total transaction of $699,728.25. Following the completion of the transaction, the insider directly owned 132,305 shares in the company, valued at $6,624,511.35. This represents a 9.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 206,696 shares of company stock worth $10,079,058. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VCYT. Osaic Holdings Inc. grew its stake in Veracyte by 289.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock worth $33,000 after buying an additional 893 shares during the last quarter. Empowered Funds LLC bought a new stake in Veracyte in the fourth quarter valued at $42,000. Smartleaf Asset Management LLC boosted its holdings in shares of Veracyte by 159.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 679 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Veracyte by 74.8% during the second quarter. Headlands Technologies LLC now owns 2,824 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,208 shares during the period. Finally, State of Wyoming bought a new position in shares of Veracyte during the fourth quarter worth about $81,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VCYT shares. Wall Street Zen raised shares of Veracyte from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Wolfe Research initiated coverage on shares of Veracyte in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 price target on the stock. Jefferies Financial Group initiated coverage on Veracyte in a research note on Monday, April 13th. They issued a “buy” rating and a $45.00 price target for the company. Needham & Company LLC boosted their price objective on Veracyte from $57.00 to $69.00 and gave the company a “buy” rating in a report on Friday. Finally, Piper Sandler started coverage on Veracyte in a research note on Wednesday, July 15th. They set an “overweight” rating and a $66.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Veracyte currently has a consensus rating of “Moderate Buy” and an average target price of $57.38.

Veracyte News Summary

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.54 per share, above the $0.43 analyst consensus and up from $0.44 a year earlier. Revenue of $150.3 million also exceeded estimates of approximately $144.6 million. Veracyte Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Total revenue increased 15% year over year, while testing revenue rose 19% to $145.7 million, indicating continued demand for Veracyte’s diagnostic testing business. Veracyte Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 revenue guidance to $590 million-$596 million, above the prior outlook implied by the approximately $585 million analyst consensus. Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Neutral Sentiment: The earnings call and presentation provided additional detail on quarterly performance and the raised 2026 outlook, but investors may be looking for further evidence that growth can accelerate beyond the current guidance range. Veracyte Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite beating quarterly estimates and raising revenue guidance, commentary questioning whether Veracyte is now fully valued suggests the results may not have exceeded the high expectations embedded in the stock. With shares trading at a relatively demanding earnings multiple, investors appear to be taking profits on the news. Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.